Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: Comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization

Histopathology

Volumn 55, Issue 6, 2009, Pages 716-723

  Mayr, Doris ^a   Heim, Sibylle ^a   Weyrauch, Kerstin ^b   Zeindl Eberhart, Evelyn ^a   Kunz, Anne ^c   Engel, Jutta ^c   Kirchner, Thomas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b ZytoVision GmbH   (Germany)

^c Cancer Registry   (Germany)

Author keywords

Breast cancer; Dual colour CISH; FISH; Her 2 neu; Immunohistochemistry

Indexed keywords

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA; CHI-SQUARE DISTRIBUTION; CHROMOGENIC COMPOUNDS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NEOPLASM STAGING; RECEPTOR, ERBB-2; RNA, MESSENGER;

EID: 70849095999     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03427.x     Document Type: Article

References (24)

1. Sauer T, Wiedswang G, Boudjema G, Christensen H, Karesen R. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice? Apmis 2003 111 444 450.
2. Formenti SC, Spicer D, Skinner K et al. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002 52 397 405.
3. Gasparini G, Longo R, Torino F, Morabito A. Therapy of breast cancer with molecular targeting agents. Ann. Oncol. 2005 16 (Suppl. 4 iv28 iv36.
4. Gusterson BA, Gelber RD, Goldhirsch A et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J. Clin. Oncol. 1992 10 1049 1056.
5. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 1998 52 65 77.
6. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994 54 2771 2777.
7. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996 13 63 72.
8. Tanner M, Gancberg D, Di Leo A et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am. J. Pathol. 2000 157 1467 1472.
9. Park K, Kim J, Lim S, Han S, Lee JY. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod. Pathol. 2003 16 937 943.
10. Isola J, Tanner M, Forsyth A et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin. Cancer Res. 2004 10 4793 4798.
11. Lambros MB, Simpson PT, Jones C et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab. Invest. 2006 86 398 408.
12. Gaiser T, Hofmann M, Stoss O, Henkel T, Ruschoff J. [Her-2/neu analysis - new data?]. Verh. Dtsch. Ges. Pathol. 2006 90 107 113.
13. Arnould L, Denoux Y, MacGrogan G et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br. J. Cancer 2003 88 1587 1591.
14. DAKO A/S and F. Hoffmann-La Roche Ltd. Atlas of interpretation of HercepTest™ staining. 2000.
15. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007 25 118 145.
16. Mayr D, Diebold J. Grading of ovarian carcinomas. Int. J. Gynecol. Pathol. 2000 19 348 353.
17. Bankfalvi A, Simon R, Brandt B et al. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology 2000 37 411 419.
18. Press MF, Slamon DJ, Flom KJ et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin. Oncol. 2002 20 3095 3105.
19. Tubbs RR, Pettay JD, Roche PC et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J. Clin. Oncol. 2001 19 2714 2721.
20. Dowsett M, Hanby AM, Laing R, Walker R. HER2 testing in the UK: consensus from a national consultation. J. Clin. Pathol. 2007 60 685 689.
21. Pauletti G, Dandekar S, Rong H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol. 2000 18 3651 3664.
22. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. 2000 13 37 45.
23. Lebeau A, Deimling D, Kaltz C et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J. Clin. Oncol. 2001 19 354 363.
24. Laakso M, Tanner M, Isola J. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J. Pathol. 2006 210 3 9.